Phaseline

Companies › ModernaTX

ModernaTX: clinical trials, targets and expected readouts

23 active drug programs in 33 registered trials: 21 Phase 1, 5 Phase 4, 5 Phase 2, 2 Phase 3; Infectious disease, Oncology, Metabolic and endocrine, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tozinameran (mRNA-1273)
Spike glycoprotein vaccine antigen
–Phase 4SARS-CoV-2Dec 2026
mRNA-1283
mRNA vaccine
–Phase 4SARS-CoV-2Dec 2026
mRNA-1273 Variant-containing Formulation
mRNA vaccine encoding SARS-CoV-2 spike protein variants
–Phase 4SARS-CoV-2Dec 2026
mRNA-1018-H5
mRNA vaccine encoding influenza H5 hemagglutinin
–Phase 3InfluenzaJan 2027
mRNA-1403
mRNA vaccine encoding norovirus virus-like particles
–Phase 3Acute Gastroenteritis; Norovirus Acute GastroenteritisFeb 2027
mRNA-1647
mRNA vaccine expressing CMV antigens
CMVPhase 2Cytomegalovirus InfectionMar 2027
mRNA-4157
Personalized neoantigen mRNA vaccine
–Phase 2Melanoma; Solid TumorsNov 2027
mRNA-1982
mRNA vaccine targeting Borrelia burgdorferi outer surface protein A (OspA)
–Phase 2Lyme DiseaseNov 2028
mRNA-1195.1
mRNA vaccine encoding Epstein-Barr virus (EBV) antigens - formulation variant
–Phase 2Multiple Sclerosis; Epstein-Barr Virus InfectionJan 2029
mRNA-3745
mRNA therapy encoding glucose-6-phosphatase
G6PCPhase 1Glycogen Storage DiseaseNov 2026
mRNA-0184
mRNA therapeutic
–Phase 1Healthy ParticipantsDec 2026
mRNA-1189
mRNA vaccine encoding Epstein-Barr virus antigens
EBNA1, LMP1, BZLF1Phase 1Epstein-Barr Virus Infection; Epstein-Barr VirusMay 2027
mRNA-1365 (Profile 2)
mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)
RSV, HMPVPhase 1Respiratory Syncytial Virus (RSV); Respiratory Syncytial VirusJul 2027
mRNA-4106
Personalized neoantigen mRNA vaccine
–Phase 1Advanced Solid TumorsAug 2027
mRNA-4200
Personalized neoantigen mRNA vaccine
–Phase 1Advanced Solid TumorsAug 2027
mRNA-3927
mRNA therapy encoding propionyl-CoA carboxylase beta subunit
PCCBPhase 1Propionic AcidemiaAug 2027
mRNA-1469
mRNA vaccine expressing Ebola-Bundibugyo virus antigens
–Phase 1Ebola-Bundibugyo Virus Disease (Ebola-BDBV)Sep 2027
mRNA-1010
mRNA vaccine encoding seasonal influenza antigens
–Phase 1Seasonal InfluenzaDec 2027
mRNA-1345
mRNA vaccine targeting respiratory syncytial virus (RSV)
RSVPhase 1Respiratory Syncytial VirusAug 2029
mRNA-2808
Immunomodulatory mRNA therapeutic
–Phase 1Relapsed or Refractory Multiple MyelomaJun 2030
mRNA-4359
Personalized neoantigen vaccine
–Phase 1Advanced Solid TumorsFeb 2032
mRNA-3705
modified mRNA encoding human methylmalonyl-coenzyme A mutase (MUT)
MMUTPhase 1Methylmalonic AcidemiaApr 2034
mRNA-1405
mRNA vaccine encoding norovirus antigens
–Phase 1Norovirus Acute Gastroenteritis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05992935mRNA-1403Phase 1Norovirus Acute GastroenteritisInfectious diseaseOct 2026
NCT05992935mRNA-1405Phase 1Norovirus Acute GastroenteritisInfectious diseaseOct 2026
NCT05831111mRNA-1189Phase 1Epstein-Barr Virus InfectionInfectious diseaseOct 2026
NCT05831111mRNA-1195.1Phase 1Epstein-Barr Virus InfectionInfectious diseaseOct 2026
NCT05095727mRNA-3745Phase 1Glycogen Storage DiseaseMetabolic and endocrineNov 2026
NCT07863635mRNA-1283Phase 4SARS-CoV-2Infectious diseaseDec 2026
NCT07863635Tozinameran (mRNA-1273)Phase 4SARS-CoV-2Infectious diseaseDec 2026
NCT06655870mRNA-0184Phase 1Healthy ParticipantsOtherDec 2026
NCT06585241mRNA-1273 Variant-containing FormulationPhase 4SARS-CoV-2Infectious diseaseDec 2026
NCT07496450mRNA-1018-H5Phase 3InfluenzaInfectious diseaseJan 2027
NCT06592794mRNA-1403Phase 3Acute GastroenteritisInfectious diseaseFeb 2027
NCT05683457mRNA-1647Phase 2Cytomegalovirus InfectionInfectious diseaseMar 2027
NCT07478952mRNA-1189Phase 1Epstein-Barr VirusInfectious diseaseMay 2027
NCT07266558mRNA-1283Phase 4SARS-CoV-2Infectious diseaseJun 2027
NCT07266558Tozinameran (mRNA-1273)Phase 4SARS-CoV-2Infectious diseaseJun 2027
NCT07764237mRNA-1365 (Profile 2)Phase 1Respiratory Syncytial Virus (RSV)Infectious diseaseJul 2027
NCT06880549mRNA-4106Phase 1Advanced Solid TumorsOncologyAug 2027
NCT06880549mRNA-4200Phase 1Advanced Solid TumorsOncologyAug 2027
NCT05164094mRNA-1189Phase 1Epstein-Barr Virus InfectionInfectious diseaseAug 2027
NCT04159103mRNA-3927Phase 1Propionic AcidemiaMetabolic and endocrineAug 2027
NCT07737717mRNA-1469Phase 1Ebola-Bundibugyo Virus Disease (Ebola-BDBV)Infectious diseaseSep 2027
NCT03313778mRNA-4157Phase 1Solid TumorsOncologyNov 2027
NCT07870330mRNA-1010Phase 1Seasonal InfluenzaInfectious diseaseDec 2027
NCT07561294mRNA-1982Phase 2Lyme DiseaseInfectious diseaseNov 2028
NCT06735248mRNA-1195.1Phase 2Multiple SclerosisNeurologyJan 2029
NCT07808697mRNA-1283Phase 2SARS-CoV-2Infectious diseaseAug 2029
NCT05743881mRNA-1365 (Profile 2)Phase 1Respiratory Syncytial VirusInfectious diseaseAug 2029
NCT05743881mRNA-1345Phase 1Respiratory Syncytial VirusInfectious diseaseAug 2029
NCT05130437mRNA-3927Phase 1Propionic AcidemiaMetabolic and endocrineDec 2029
NCT07116616mRNA-2808Phase 1Relapsed or Refractory Multiple MyelomaOncologyJun 2030
NCT05533697mRNA-4359Phase 1Advanced Solid TumorsOncologyFeb 2032
NCT03897881mRNA-4157Phase 2MelanomaOncologyNov 2032
NCT05295433mRNA-3705Phase 1Methylmalonic AcidemiaMetabolic and endocrineApr 2034

From the company's SEC filings

Cash and short-term investments of $5.2bn on 2026-09-30; operating cash outflow about $3.6bn a year; runway about 17 months at that burn, to Feb 2028; 3 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

RSV (2) CMV (1) EBNA1 (1) LMP1 (1) BZLF1 (1) PCCB (1) G6PC (1) HMPV (1) MMUT (1)

Companies with the same targets

Sanofi AstraZeneca MAXVAX Biotechnology Limited Liability Company Enanta Pharmaceuticals Shenzhen Shenxin Biotechnology GSK

Companies built like this

CanSino Biologics Anhui Zhifei Longcom Biologic Pharmacy Precigen InventVacc Biologicals MAXVAX Biotechnology Limited Liability Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.